Vor Biopharma (NYSE:VOR) Shares Up 5.9%

Vor Biopharma Inc. (NYSE:VORGet Free Report)’s share price was up 5.9% during trading on Monday . The stock traded as high as $1.47 and last traded at $1.43. Approximately 635,734 shares were traded during trading, an increase of 118% from the average daily volume of 291,863 shares. The stock had previously closed at $1.35.

Analysts Set New Price Targets

VOR has been the subject of a number of analyst reports. Stifel Nicolaus decreased their price objective on Vor Biopharma from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. JMP Securities reissued a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research note on Monday, May 13th. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Vor Biopharma in a report on Friday, May 10th. HC Wainwright restated a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research report on Thursday, March 21st. Finally, Oppenheimer reiterated an “outperform” rating and set a $10.00 target price (down from $15.00) on shares of Vor Biopharma in a report on Monday, May 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $12.50.

Get Our Latest Report on VOR

Vor Biopharma Price Performance

The company has a market capitalization of $89.42 million, a price-to-earnings ratio of -0.74 and a beta of -0.29. The firm has a 50-day moving average price of $1.78 and a two-hundred day moving average price of $2.03.

Vor Biopharma (NYSE:VORGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.08). On average, equities analysts predict that Vor Biopharma Inc. will post -1.49 EPS for the current year.

Institutional Trading of Vor Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Vor Biopharma by 4.0% in the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after acquiring an additional 69,436 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Vor Biopharma in the 1st quarter valued at about $126,000. Finally, Exchange Traded Concepts LLC lifted its stake in Vor Biopharma by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 60,170 shares of the company’s stock valued at $135,000 after purchasing an additional 15,258 shares during the last quarter. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

Further Reading

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.